Your session is about to expire
← Back to Search
cyclophosphamide for Ovarian Cancer
Study Summary
This trial is studying the combination of cyclophosphamide and celecoxib to see how well it works compared to cyclophosphamide alone in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned or does not respond to treatment.
- Ovarian Cancer
- Peritoneal Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 2 trial • 303 Patients • NCT02004262Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What ailments is cyclophosphamide commonly prescribed to treat?
"Cyclophosphamide is an effective therapeutic agent for multiple sclerosis, leukemia, myelocytic disorders, acute illnesses and retinoblastoma."
What other investigations have been conducted into the efficacy of cyclophosphamide?
"Currently, 851 clinical trials are underway researching the potential of cyclophosphamide. Of these investigations, 160 have moved into Phase 3. The vast majority of studies for this medication take place in Philadelphia, however there are 28,958 research sites conducting tests on its efficacy."
Are there still opportunities to join this research endeavor?
"Unfortunately, this investigation is not currently recruiting subjects. The study began on December 22nd 2003 and was last updated March 17th 2022; if you are looking for other opportunities there are presently 1435 trials seeking participants with peritoneal cavity cancer and 851 studies accepting patients treated with cyclophosphamide."
How many participants have enrolled in this research project?
"The enrollment period for this trial has since expired, as the last update was posted on March 17th 2022. However, there are currently 1435 studies recruiting patients with peritoneal cavity cancer and 851 clinical trials looking for participants who have been treated with cyclophosphamide."
Is cyclophosphamide authorized by the FDA?
"Cyclophosphamide has been assigned a safety rating of 2 on the Power scale, as there is evidence to suggest that it is safe but no studies have yet established its efficacy."
Share this study with friends
Copy Link
Messenger